{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T18:46:09Z","timestamp":1780080369536,"version":"3.54.0"},"reference-count":108,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004286","name":"Santen Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004286","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.survophthal.2025.03.003","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T20:12:10Z","timestamp":1742242330000},"page":"918-929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical implications of lowering episcleral venous pressure in the management of glaucoma and the use of Rho kinase inhibitors"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3904-2625","authenticated-orcid":false,"given":"Arthur J.","family":"Sit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Aihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony P.","family":"Khawaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan C.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaweh","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuya","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Ho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert N.","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.survophthal.2025.03.003_bib1","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/S0161-6420(98)91224-6","article-title":"Topical verapamil and episcleral venous pressure","volume":"105","author":"Abreu","year":"1998","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.003_bib2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1076\/ceyr.27.6.355.18194","article-title":"Episcleral venous pressure of mouse eye and effect of body position","volume":"27","author":"Aihara","year":"2003","journal-title":"Curr Eye Res"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.003_bib3","first-page":"146","article-title":"Reduction of intraocular pressure in mouse eyes treated with latanoprost","volume":"43","author":"Aihara","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2025.03.003_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2147\/JEP.S259297","article-title":"Investigational Rho kinase inhibitors for the treatment of glaucoma","volume":"13","author":"Al-Humimat","year":"2021","journal-title":"J Exp Pharm"},{"issue":"10","key":"10.1016\/j.survophthal.2025.03.003_bib5","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1007\/s12325-023-02550-w","article-title":"Phase 3 clinical trail comparing the safety and efficacy of netarsudil to ripasudil in patients with primary open-angle glaucoma or ocular hypertension: Japan Rho-kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET)","volume":"40","author":"Araie","year":"2023","journal-title":"Adv Ther"},{"issue":"12","key":"10.1016\/j.survophthal.2025.03.003_bib6","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1167\/iovs.17-22154","article-title":"Effect of body position on episcleral venous pressure in healthy subjects","volume":"58","author":"Arora","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2025.03.003_bib7","doi-asserted-by":"crossref","first-page":"xxix","DOI":"10.1016\/j.ajo.2018.05.025","article-title":"The aqueous veins: I. Physiologic importance of the visible elimination of intraocular fluid","volume":"192","author":"Ascher","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2025.03.003_bib8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/bjo.35.5.291","article-title":"Anatomical study of Schlemm\u2019s canal and aqueous veins by means of neoprene casts. Part I. Aqueous veins","volume":"35","author":"Ashton","year":"1951","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.003_bib9","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s12325-020-01277-2","article-title":"Fixed-dose combination of netarsudil and latanoprost in ocular hypertension and open-angle glaucoma: pooled efficacy\/safety analysis of phase 3 MERCURY-1 and -2","volume":"37","author":"Asrani","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.survophthal.2025.03.003_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2024.101303","article-title":"The relationship between intraocular pressure and glaucoma: an evolving concept","volume":"103","author":"Asrani","year":"2024","journal-title":"Prog Retin Eye Res"},{"issue":"8","key":"10.1016\/j.survophthal.2025.03.003_bib11","first-page":"1841","article-title":"Reliable measurement of mouse intraocular pressure by a servo-null micropipette system","volume":"42","author":"Avila","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.003_bib12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ophtha.2014.08.022","article-title":"AR-13324-CS202 Study Group. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure","volume":"122","author":"Bacharach","year":"2015","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.survophthal.2025.03.003_bib13","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1167\/iovs.08-1707","article-title":"Reduction of the available area for aqueous humor outflow and increase in meshwork herniations into collector channels following acute IOP elevation in bovine eyes","volume":"49","author":"Battista","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2025.03.003_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/705915","article-title":"Update on minimally invasive glaucoma surgery (MIGS) and new implants","volume":"2013","author":"Brand\u00e3o","year":"2013","journal-title":"J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.003_bib15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1001\/archopht.1967.00980020112024","article-title":"Determination of episcleral venous pressure in the eye. A comparison of three methods","volume":"77","author":"Brubaker","year":"1967","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.003_bib16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.exer.2003.07.002","article-title":"Goldmann\u2019s equation and clinical measures of aqueous dynamics","volume":"78","author":"Brubaker","year":"2004","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.survophthal.2025.03.003_bib17","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0039-6257(03)00003-1","article-title":"Targeting outflow facility in glaucoma management","author":"Brubaker","year":"2003","journal-title":"Surv Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.003_bib18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/APO.0000000000000646","article-title":"Minimally invasive glaucomaa surgery: latest developments and future challenges","volume":"12","author":"Chan","year":"2023","journal-title":"Asia Pac J Ophthalmol (Philos"},{"issue":"12","key":"10.1016\/j.survophthal.2025.03.003_bib19","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/j.ophtha.2015.08.038","article-title":"Episcleral venous fluid wave correlates with Trabectome outcomes: intraoperative evaluation of the trabecular outflow pathway","volume":"122","author":"Fellman","year":"2015","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.003_bib20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0002-9394(14)74275-8","article-title":"Intraocular and episcleral venous pressure increase during inverted posture","volume":"103","author":"Friberg","year":"1987","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2025.03.003_bib21","first-page":"848","article-title":"Studies of aqueous humor dynamics in man. IV. Effects of pilocarpine upon measurements in young normal volunteers","volume":"14","author":"Gaasterland","year":"1975","journal-title":"Invest Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2025.03.003_bib22","first-page":"1417","article-title":"Episcleral venous pressure: a comparison of invasive and noninvasive measurements","volume":"24","author":"Gaasterland","year":"1983","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2025.03.003_bib23","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.2147\/OPTH.S103985","article-title":"Critical evaluation of latanoprostene bunod in the treatment of glaucoma","volume":"10","author":"Garcia","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.03.003_bib24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/1874364101004010052","article-title":"Aqueous humor dynamics: a review","volume":"4","author":"Goel","year":"2010","journal-title":"Open Ophthalmol J"},{"key":"10.1016\/j.survophthal.2025.03.003_bib25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s40135-018-0168-1","article-title":"New technology and current understanding of episcleral venous pressure","volume":"6","author":"Greenwood","year":"2018","journal-title":"Curr Ophthalmol Rep"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.003_bib26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/112067210001000201","article-title":"A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol","volume":"10","author":"Hedman","year":"2000","journal-title":"Eur J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.003_bib27","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1167\/iovs.09-4391","article-title":"Divergent roles of nitric oxide and Rho kinase in vasomotor regulation of human retinal arterioles","volume":"51","author":"Hein","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"10.1016\/j.survophthal.2025.03.003_bib28","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1007\/s12325-014-0151-7","article-title":"Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products","volume":"31","author":"Holl\u00f3","year":"2014","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.003_bib29","first-page":"137","article-title":"Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility","volume":"42","author":"Honjo","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"10.1016\/j.survophthal.2025.03.003_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1167\/iovs.65.10.17","article-title":"Activation of the ROCK\/MYLK pathway affects complex molecular and morphological changes of the trabecular meshwork associated with ocular hypertension","volume":"65","author":"Hsu","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.survophthal.2025.03.003_bib31","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.ophtha.2017.03.058","article-title":"Aqueous angiography: aqueous humor outflow imaging in live human subjects","volume":"124","author":"Huang","year":"2017","journal-title":"Ophthalmology"},{"issue":"10108","key":"10.1016\/j.survophthal.2025.03.003_bib32","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/S0140-6736(17)31469-1","article-title":"Glaucoma","volume":"390","author":"Jonas","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.survophthal.2025.03.003_bib33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajo.2019.01.003","article-title":"ROCKET-2 Study Group. Long-term safety and ocular hypotensive efficacy evaluation of netarsudil ophthalmic solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)","volume":"200","author":"Kahook","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.003_bib34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/14728214.2022.2110240","article-title":"Emerging drugs for the treatment of glaucoma: a review of phase II & III trials","volume":"27","author":"Kaplan","year":"2022","journal-title":"Expert Opin Emerg Drugs"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.003_bib35","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2025.03.003_bib36","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1177\/11206721231159694","article-title":"Topical netarsudil for treatment of glaucoma with elevated episcleral venous pressure: a pilot investigation in Sturge-Weber syndrome","volume":"33","author":"Kaufman","year":"2023","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2025.03.003_bib37","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1089\/jop.2017.0138","article-title":"The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans","volume":"34","author":"Kazemi","year":"2018","journal-title":"J Ocul Pharm Ther"},{"issue":"13","key":"10.1016\/j.survophthal.2025.03.003_bib38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1167\/iovs.62.13.4","article-title":"Effect of topical phenylephrine 2.5% on episcleral venous pressure in normal human eyes","volume":"62","author":"Kazemi","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2025.03.003_bib39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ajo.2019.03.002","article-title":"ROCKET-4 Study Group. Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study","volume":"204","author":"Khouri","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.003_bib40","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/jop.2014.0146","article-title":"Effect of AR-13324 on episcleral venous pressure in Dutch belted rabbits","volume":"31","author":"Kiel","year":"2015","journal-title":"J Ocul Pharm Ther"},{"issue":"5","key":"10.1016\/j.survophthal.2025.03.003_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100533","article-title":"Netarsudil 0.02% alters episcleral venous flowrates: a clinical trial using erythrocyte-mediated angiography","volume":"4","author":"Kim","year":"2024","journal-title":"Ophthalmol Sci"},{"issue":"7","key":"10.1016\/j.survophthal.2025.03.003_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132048","article-title":"The prevalence and incidence of glaucoma in Denmark in a fifteen year period: a nationwide study","volume":"10","author":"Kolko","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.003_bib43","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1755-3768.1973.tb03796.x","article-title":"Measuremetns of the episcleral venous pressure by means of an air jet","volume":"51","author":"Krakau","year":"1973","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"7","key":"10.1016\/j.survophthal.2025.03.003_bib44","first-page":"523","article-title":"Studies of aqueous humor dynamics in man. II. Measurements in young normal subjects using acetazolamide and L-epinephrine","volume":"10","author":"Kupfer","year":"1971","journal-title":"Invest Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.003_bib45","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00417-018-3933-9","article-title":"Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma","volume":"256","author":"Kusuhara","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2025.03.003_bib46","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/IJG.0000000000001307","article-title":"Episcleral venous pressure and the ocular hypotensive effects of topical and intracameral prostaglandin analogs","volume":"28","author":"Lee","year":"2019","journal-title":"J Glaucoma"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.003_bib47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ogla.2020.01.005","article-title":"Netarsudil\u2019s effect in eyes with a history of selective laser trabeculoplasty","volume":"3","author":"Lin","year":"2020","journal-title":"Ophthalmol Glaucoma"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.003_bib48","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1755-3768.1950.tb00002.x","article-title":"Werner H. Comparative measurements of the pressure in the aqueous veins and the conjunctival veins using different methods","volume":"28","author":"Linner","year":"1950","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.003_bib49","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ajo.2004.04.022","article-title":"Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure","volume":"138","author":"Liu","year":"2004","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2025.03.003_bib50","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.ophtha.2010.03.026","article-title":"Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure","volume":"117","author":"Liu","year":"2010","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.survophthal.2025.03.003_bib51","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1167\/iovs.14-16325","article-title":"Effect of topical anesthesia on episcleral venous pressure in normal human subjects","volume":"56","author":"Malihi","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.003_bib52","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40261-017-0509-0","article-title":"Efficacy of ripasudil as a second-line medication in addition to a prostaglandin analog in patients with exfoliation glaucoma: a pilot study","volume":"37","author":"Matsumura","year":"2017","journal-title":"Clin Drug Invest"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.003_bib53","doi-asserted-by":"crossref","first-page":"C44","DOI":"10.1152\/ajpcell.00024.2018","article-title":"Pharmacological regulation of outflow resistance distal to Schlemm\u2019s canal","volume":"315","author":"McDonnell","year":"2018","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.003_bib54","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41433-019-0671-0","article-title":"New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost","volume":"34","author":"Mehran","year":"2020","journal-title":"Eye (Lond)"},{"issue":"10","key":"10.1016\/j.survophthal.2025.03.003_bib55","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/IJG.0000000000002465","article-title":"Expert consensus recommendations for the management of ocular surface inflammation in patients with glaucoma","volume":"33","author":"Messmer","year":"2024","journal-title":"J Glaucoma"},{"key":"10.1016\/j.survophthal.2025.03.003_bib56","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5005\/jp-journals-10008-1002","article-title":"Episcleral venous pressure and glaucoma","volume":"3","author":"Moster","year":"2009","journal-title":"J Curr Glaucoma Pr"},{"issue":"9","key":"10.1016\/j.survophthal.2025.03.003_bib57","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.3390\/ijms22094662","article-title":"Vascular aspects in glaucoma: from pathogenesis to therapeutic approaches","volume":"22","author":"Mursch-Edlmayr","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.survophthal.2025.03.003_bib58","first-page":"7623","article-title":"Circadian variation of aqueous humor dynamics in older healthy adults","volume":"54","author":"Nau","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.003_bib59","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jcjo.2023.05.009","article-title":"Effectiveness of netarsudil 0.02% in lowering intraocular pressure in patients with secondary glaucoma","volume":"59","author":"Oydanich","year":"2024","journal-title":"Can J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.003_bib60","article-title":"Morphological changes in the trabecular meshwork and Schlemm\u2019s canal after treatment with topical intraocular pressure-lowering agents","volume":"11","author":"Park","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.003_bib61","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40123-020-00322-1","article-title":"A randomized, phase 2 study of 24-h efficacy and tolerability of netarsudil in ocular hypertension and open-angle glaucoma","volume":"10","author":"Peace","year":"2021","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.003_bib62","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0002-9394(14)76662-0","article-title":"Measurement of episcleral venous pressure","volume":"85","author":"Phelps","year":"1978","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.003_bib63","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archopht.1968.00980050211011","article-title":"A new instrument to measure episcleral venous pressure. Comparison of normal eyes and eyes with primary open-angle glaucoma","volume":"80","author":"Podos","year":"1968","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.03.003_bib64","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.exer.2016.08.023","article-title":"Role of the Rho GTPase\/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: bench to bedside research","volume":"158","author":"Rao","year":"2017","journal-title":"Exp Eye Res"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.003_bib65","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.exer.2005.07.015","article-title":"Effects of a topical alpha2 adrenergic agonist on ciliary blood flow and aqueous production in rabbits","volume":"82","author":"Reitsamer","year":"2006","journal-title":"Exp Eye Res"},{"issue":"14","key":"10.1016\/j.survophthal.2025.03.003_bib66","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1167\/iovs.16-20189","article-title":"Netarsudil increases outflow facility in human eyes through multiple mechanisms","volume":"57","author":"Ren","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"10.1016\/j.survophthal.2025.03.003_bib67","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3109\/02713688909013902","article-title":"Outflow resistance of enucleated human eyes at two different perfusion pressures and different extents of trabeculotomy","volume":"8","author":"Rosenquist","year":"1989","journal-title":"Curr Eye Res"},{"issue":"11","key":"10.1016\/j.survophthal.2025.03.003_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141783","article-title":"Ocular hypotensive effects of the ATP-sensitive potassium channel opener cromakalim in human and murine experimental model systems","volume":"10","author":"Roy Chowdhury","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.survophthal.2025.03.003_bib69","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/jop.2020.0137","article-title":"Pharmacological profile and ocular hypotensive effects of cromakalim prodrug 1, a novel ATP-sensitive potassium channel opener, in normotensive dogs and nonhuman primates","volume":"37","author":"Roy Chowdhury","year":"2021","journal-title":"J Ocul Pharm Ther"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.003_bib70","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1167\/iovs.63.2.15","article-title":"Effect of ATP-sensitive potassium channel openers on intraocular pressure in ocular hypertensive animal models","volume":"63","author":"Roy Chowdhury","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.003_bib71","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1038\/s41598-019-40255-9","article-title":"Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% ripasudil ophthalmic solution clinical trial","volume":"9","author":"Sakamoto","year":"2019","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.survophthal.2025.03.003_bib72","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1007\/s12325-021-01775-x","article-title":"The additive effect of ROCK inhibitor on prostaglandin-treated Japanese patients with glaucoma indicating 15 mmHg and under: ROCK U-15","volume":"38","author":"Sakata","year":"2021","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.003_bib73","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/17469899.2016.1180246","article-title":"What rates of glaucoma progression are clinically significant?","volume":"11","author":"Saunders","year":"2016","journal-title":"Expert Rev Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.003_bib74","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1159\/000088378","article-title":"Episcleral venous pressure in untreated primary open-angle and normal-tension glaucoma","volume":"219","author":"Selbach","year":"2005","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.survophthal.2025.03.003_bib75","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","article-title":"ROCKET-1 and ROCKET-2 Study Groups. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)","volume":"186","author":"Serle","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2025.03.003_bib76","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/IJG.0000000000001634","article-title":"Pooled efficacy and safety profile of netarsudil ophthalmic solution 0.02% in patients with open-angle glaucoma or ocular hypertension","volume":"29","author":"Singh","year":"2020","journal-title":"J Glaucoma"},{"key":"10.1016\/j.survophthal.2025.03.003_bib77","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.survophthal.2008.08.009","article-title":"Effects of medications and surgery on intraocular pressure fluctuation","author":"Sit","year":"2008","journal-title":"Surv Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.03.003_bib78","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.exer.2011.03.018","article-title":"A novel method for computerized measurement of episcleral venous pressure in humans","volume":"92","author":"Sit","year":"2011","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.survophthal.2025.03.003_bib79","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ajo.2021.01.019","article-title":"Netarsudil improves trabecular outflow facility in patients with primary open angle glaucoma or ocular hypertension: a phase 2 study","volume":"226","author":"Sit","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.003_bib80","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.exer.2011.05.003","article-title":"Measurement of episcleral venous pressure","volume":"93","author":"Sit","year":"2011","journal-title":"Exp Eye Res"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.003_bib81","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0002-9394(00)00401-3","article-title":"Effects of latanoprost and timolol-XE on hydrodynamics in the normal eye","volume":"130","author":"Sponsel","year":"2000","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.003_bib82","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1590\/S0004-27492013000100013","article-title":"Idiopathic dilated episcleral vessels (Radius-Maumenee syndrome): case report","volume":"76","author":"Stock","year":"2013","journal-title":"Arq Bras Oftalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.003_bib83","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/00061198-200308000-00013","article-title":"Episcleral venous pressure in younger and older subjects in the sitting and supine positions","volume":"12","author":"Sultan","year":"2003","journal-title":"J Glaucoma"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.003_bib84","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-19271-9","article-title":"Aqueous column changes in the episcleral veins after the instillation of ripasudil versus latanoprost: a randomized, double\u2011blind, crossover clinical trial","volume":"12","author":"Suzuki","year":"2022","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.survophthal.2025.03.003_bib85","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jamaophthalmol.2013.323","article-title":"K-115 Clinical Study Group. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115","volume":"131","author":"Tanihara","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.003_bib86","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","article-title":"K-115 Clinical Study Group. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension","volume":"156","author":"Tanihara","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.003_bib87","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/aos.12829","article-title":"K-115 Clinical Study Group. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension","volume":"94","author":"Tanihara","year":"2016","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2025.03.003_bib88","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","article-title":"K-115 Clinical Study Group. Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials","volume":"133","author":"Tanihara","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.003_bib89","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/aos.12599","article-title":"K-115 Clinical Study Group. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24\u2009h in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study","volume":"93","author":"Tanihara","year":"2015","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.003_bib90","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s12325-021-02023-y","article-title":"Long-term intraocular pressure-lowering effects and adverse events of ripasudil in patients with glaucoma or ocular hypertension over 24 months","volume":"39","author":"Tanihara","year":"2022","journal-title":"Adv Ther"},{"issue":"11","key":"10.1016\/j.survophthal.2025.03.003_bib91","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.ophtha.2018.04.040","article-title":"Rho kinase inhibitors as a novel treatment for glaucoma and ocular hypertension","volume":"125","author":"Tanna","year":"2018","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.survophthal.2025.03.003_bib92","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.003_bib93","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/17469899.2021.1902308","article-title":"Current methods and new approaches to assess aqueous humor dynamics","volume":"16","author":"Toris","year":"2021","journal-title":"Exp Rev Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2025.03.003_bib94","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1001\/archopht.1995.01100120044006","article-title":"Effects of brimonidine on aqueous humor dynamics in human eyes","volume":"113","author":"Toris","year":"1995","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.003_bib95","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0161-6420(95)31000-7","article-title":"Effects of apraclonidine on aqueous humor dynamics in human eyes","volume":"102","author":"Toris","year":"1995","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2025.03.003_bib96","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0002-9394(98)00436-X","article-title":"Aqueous humor dynamics in the aging human eye","volume":"127","author":"Toris","year":"1999","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2025.03.003_bib97","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/archopht.122.12.1782","article-title":"Increase in outflow facility with unoprostone treatment in ocular hypertensive patients","volume":"122","author":"Toris","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.03.003_bib98","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/IJG.0b013e31802fc6d3","article-title":"Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure","volume":"16","author":"Toris","year":"2007","journal-title":"J Glaucoma"},{"key":"10.1016\/j.survophthal.2025.03.003_bib99","first-page":"883","article-title":"An emerging treatment option for glaucoma: Rho kinase inhibitors","volume":"8","author":"Wang","year":"2014","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.003_bib100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/IJG.0b013e3182952213","article-title":"Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes","volume":"24","author":"Wang","year":"2015","journal-title":"J Glaucoma"},{"issue":"5","key":"10.1016\/j.survophthal.2025.03.003_bib101","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/00061198-200010000-00001","article-title":"Uveoscleral outflow: the other outflow pathway","volume":"9","author":"Weinreb","year":"2000","journal-title":"J Glaucoma"},{"issue":"18","key":"10.1016\/j.survophthal.2025.03.003_bib102","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.survophthal.2025.03.003_bib103","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1007\/s00417-022-05609-6","article-title":"Response to netarsudil in goniotomy-treated eyes and goniotomy-na\u00efve eyes: a pilot study","volume":"260","author":"Xu","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.003_bib104","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0014-4835(87)80024-6","article-title":"The effect of levobunolol on aqueous humor dynamics","volume":"44","author":"Yablonski","year":"1987","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.survophthal.2025.03.003_bib105","first-page":"2712","article-title":"Effect of IOP-lowering drugs on episcleral venous pressure in mouse eye","volume":"59","author":"Yamagishi","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.survophthal.2025.03.003_bib106","doi-asserted-by":"crossref","first-page":"7861","DOI":"10.1038\/s41598-024-58212-6","article-title":"Effect of a fixed combination of ripasudil and brimonidine on aqueous humor dynamics in mice","volume":"14","author":"Yamagishi-Kimura","year":"2024","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.survophthal.2025.03.003_bib107","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1167\/iovs.09-4530","article-title":"Episcleral venous pressure responses to topical nitroprusside and N-nitro-l-arginine methyl ester","volume":"51","author":"Zamora","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"10.1016\/j.survophthal.2025.03.003_bib108","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1001\/archopht.1983.01040020449024","article-title":"A practical venomanometer. Measurement of episcleral venous pressure and assessment of the normal range","volume":"101","author":"Zeimer","year":"1983","journal-title":"Arch Ophthalmol"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625725000529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625725000529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T01:30:13Z","timestamp":1762219813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625725000529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":108,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0039625725000529"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.03.003","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical implications of lowering episcleral venous pressure in the management of glaucoma and the use of Rho kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}